Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

151Citations
Citations of this article
174Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients who failed treatment with bortezomib and lenalidomide and had adequate prior alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the primary end point; secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Among 682 patients enrolled, median age was 66 years, and median time since diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8 months; median duration of treatment was 4.9 months. Most frequent grade 3/4 treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic toxicities were pneumonia (10.9%) and fatigue (5.9%). Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6% each). The ORR was 32.6%, and the median DOR was 7.4 months. Median PFS and OS were 4.6 months and 11.9 months, respectively. We present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming that this regimen offers clinically meaningful benefit and is generally well tolerated. www.Clinicaltrials.gov identifier NCT01712789.

References Powered by Scopus

Prediction of creatinine clearance from serum creatinine

13930Citations
N/AReaders
Get full text

International uniform response criteria for multiple myeloma

2398Citations
N/AReaders
Get full text

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

855Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., … Moreau, P. (2016). Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma. Blood, 128(4), 497–503. https://doi.org/10.1182/blood-2016-02-700872

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 45

54%

Researcher 26

31%

Professor / Associate Prof. 9

11%

Lecturer / Post doc 4

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 63

66%

Biochemistry, Genetics and Molecular Bi... 14

15%

Pharmacology, Toxicology and Pharmaceut... 13

14%

Nursing and Health Professions 6

6%

Article Metrics

Tooltip
Mentions
News Mentions: 3
Social Media
Shares, Likes & Comments: 13

Save time finding and organizing research with Mendeley

Sign up for free